158 related articles for article (PubMed ID: 22464845)
1. Chemotherapy in newborns and preterm babies.
Veal GJ; Boddy AV
Semin Fetal Neonatal Med; 2012 Aug; 17(4):243-248. PubMed ID: 22464845
[TBL] [Abstract][Full Text] [Related]
2. Adaptive dosing of anticancer drugs in neonates: facilitating evidence-based dosing regimens.
Veal GJ; Errington J; Sastry J; Chisholm J; Brock P; Morgenstern D; Pritchard-Jones K; Chowdhury T
Cancer Chemother Pharmacol; 2016 Apr; 77(4):685-92. PubMed ID: 26875154
[TBL] [Abstract][Full Text] [Related]
3. Carboplatin therapeutic monitoring in preterm and full-term neonates.
Veal GJ; Errington J; Hayden J; Hobin D; Murphy D; Dommett RM; Tweddle DA; Jenkinson H; Picton S
Eur J Cancer; 2015 Sep; 51(14):2022-30. PubMed ID: 26232270
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic monitoring of carboplatin dosing in a premature infant with retinoblastoma.
Picton SV; Keeble J; Holden V; Errington J; Boddy AV; Veal GJ
Cancer Chemother Pharmacol; 2009 Mar; 63(4):749-52. PubMed ID: 18607591
[TBL] [Abstract][Full Text] [Related]
5. Over a decade of experience with carboplatin therapeutic drug monitoring in a childhood cancer setting in the United Kingdom.
Barnett S; Kong J; Makin G; Veal GJ
Br J Clin Pharmacol; 2021 Feb; 87(2):256-262. PubMed ID: 32519769
[TBL] [Abstract][Full Text] [Related]
6. Review of therapeutic drug monitoring of anticancer drugs part 1--cytotoxics.
Paci A; Veal G; Bardin C; Levêque D; Widmer N; Beijnen J; Astier A; Chatelut E
Eur J Cancer; 2014 Aug; 50(12):2010-9. PubMed ID: 24889915
[TBL] [Abstract][Full Text] [Related]
7. Clinical pharmacology of cytotoxic drugs in neonates and infants: Providing evidence-based dosing guidance.
Nijstad AL; Barnett S; Lalmohamed A; Bérénos IM; Parke E; Carruthers V; Tweddle DA; Kong J; Zwaan CM; Huitema ADR; Veal GJ
Eur J Cancer; 2022 Mar; 164():137-154. PubMed ID: 34865945
[TBL] [Abstract][Full Text] [Related]
8. Investigating the potential impact of dose banding for systemic anti-cancer therapy in the paediatric setting based on pharmacokinetic evidence.
White-Koning M; Osborne C; Paci A; Boddy AV; Chatelut E; Veal GJ
Eur J Cancer; 2018 Mar; 91():56-67. PubMed ID: 29335155
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of carboplatin and etoposide in infant neuroblastoma patients.
Veal GJ; Cole M; Errington J; Pearson AD; Gerrard M; Whyman G; Ellershaw C; Boddy AV
Cancer Chemother Pharmacol; 2010 May; 65(6):1057-66. PubMed ID: 19701749
[TBL] [Abstract][Full Text] [Related]
10. Investigating current practices in renal function measurement and carboplatin dosing in children with cancer - a UK perspective.
Roberts E; Mogg JAW; Barnfield M; Veal GJ
Pediatr Hematol Oncol; 2020 Apr; 37(3):235-244. PubMed ID: 31941404
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of sequential chemotherapy including methotrexate and doxorubicin in an infant with partially resected choroid plexus carcinoma.
Fiorillo A; Maggi G; Cirillo S; Migliorati R; Buffardi F; Alfieri E; Sabbatino MS; D'Amico A; DelBasso DeCaro ML
Pediatr Neurosurg; 2003 Jan; 38(1):21-6. PubMed ID: 12476023
[TBL] [Abstract][Full Text] [Related]
12. Phase I clinical trial of the novel platin complex dicycloplatin: clinical and pharmacokinetic results.
Li S; Huang H; Liao H; Zhan J; Guo Y; Zou BY; Jiang WQ; Guan ZZ; Yang XQ
Int J Clin Pharmacol Ther; 2013 Feb; 51(2):96-105. PubMed ID: 23127487
[TBL] [Abstract][Full Text] [Related]
13. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
Edelman MJ; Meyers FJ; Houston J; Lauder I
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
[TBL] [Abstract][Full Text] [Related]
14. Phase I clinical trial of oral rosiglitazone in combination with intravenous carboplatin in cancer-bearing dogs.
Allstadt Frazier S; McKemie DS; Guerrero TA; LaChapelle H; Skorupski KA; Kass PH; Rodriguez CO
Vet Comp Oncol; 2014 Mar; 12(1):1-9. PubMed ID: 22364238
[TBL] [Abstract][Full Text] [Related]
15. Adaptive dosing and platinum-DNA adduct formation in children receiving high-dose carboplatin for the treatment of solid tumours.
Veal GJ; Errington J; Tilby MJ; Pearson AD; Foot AB; McDowell H; Ellershaw C; Pizer B; Nowell GM; Pearson DG; Boddy AV;
Br J Cancer; 2007 Mar; 96(5):725-31. PubMed ID: 17299395
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacokinetics and individual dose adjustment of carboplatin].
Chatelut E; Canal P; Bugat R
Bull Cancer; 2000 Aug; 87 Spec No():17-23. PubMed ID: 11082718
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacokinetics and dose optimisation of carboplatin.
Duffull SB; Robinson BA
Clin Pharmacokinet; 1997 Sep; 33(3):161-83. PubMed ID: 9314610
[TBL] [Abstract][Full Text] [Related]
18. Clinical trial and pharmacokinetic study of combination paclitaxel and carboplatin in patients with epithelial ovarian cancer.
Yamamoto R; Kaneuchi M; Nishiya M; Todo Y; Takeda M; Okamoto K; Negishi H; Sakuragi N; Fujimoto S; Hirano T
Cancer Chemother Pharmacol; 2002 Aug; 50(2):137-42. PubMed ID: 12172979
[TBL] [Abstract][Full Text] [Related]
19. [Carboplatin in pediatrics].
Doz F
Bull Cancer; 2000 Aug; 87 Spec No():25-9. PubMed ID: 11082719
[TBL] [Abstract][Full Text] [Related]
20. The role of therapeutic drug monitoring in the management of safety of anticancer agents: a focus on 3 cytotoxics.
Levêque D; Becker G
Expert Opin Drug Saf; 2019 Nov; 18(11):1009-1015. PubMed ID: 31478396
[No Abstract] [Full Text] [Related]
[Next] [New Search]
